These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 9373327)

  • 1. In vitro and in vivo characterisation of a recombinant carboxypeptidase G2::anti-CEA scFv fusion protein.
    Michael NP; Chester KA; Melton RG; Robson L; Nicholas W; Boden JA; Pedley RB; Begent RH; Sherwood RF; Minton NP
    Immunotechnology; 1996 Feb; 2(1):47-57. PubMed ID: 9373327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Catalytic activity of an in vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion protein.
    Bhatia J; Sharma SK; Chester KA; Pedley RB; Boden RW; Read DA; Boxer GM; Michael NP; Begent RH
    Int J Cancer; 2000 Feb; 85(4):571-7. PubMed ID: 10699932
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained tumor regression of human colorectal cancer xenografts using a multifunctional mannosylated fusion protein in antibody-directed enzyme prodrug therapy.
    Sharma SK; Pedley RB; Bhatia J; Boxer GM; El-Emir E; Qureshi U; Tolner B; Lowe H; Michael NP; Minton N; Begent RH; Chester KA
    Clin Cancer Res; 2005 Jan; 11(2 Pt 1):814-25. PubMed ID: 15701872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiolabelling of glycosylated MFE-23::CPG2 fusion protein (MFECP1) with 99mTc for quantitation of tumour antibody-enzyme localisation in antibody-directed enzyme pro-drug therapy (ADEPT).
    Francis RJ; Mather SJ; Chester K; Sharma SK; Bhatia J; Pedley RB; Waibel R; Green AJ; Begent RH
    Eur J Nucl Med Mol Imaging; 2004 Aug; 31(8):1090-6. PubMed ID: 15029458
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of the critical DNA lesions produced by antibody-directed enzyme prodrug therapy (ADEPT) in vitro, in vivo and in clinical material.
    Webley SD; Francis RJ; Pedley RB; Sharma SK; Begent RH; Hartley JA; Hochhauser D
    Br J Cancer; 2001 Jun; 84(12):1671-6. PubMed ID: 11401322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-tumour effects of an antibody-carboxypeptidase G2 conjugate in combination with phenol mustard prodrugs.
    Blakey DC; Davies DH; Dowell RI; East SJ; Burke PJ; Sharma SK; Springer CJ; Mauger AB; Melton RG
    Br J Cancer; 1995 Nov; 72(5):1083-8. PubMed ID: 7577451
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics.
    Spencer DI; Robson L; Purdy D; Whitelegg NR; Michael NP; Bhatia J; Sharma SK; Rees AR; Minton NP; Begent RH; Chester KA
    Proteomics; 2002 Mar; 2(3):271-9. PubMed ID: 11921443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Production and tumour-binding characterization of a chimeric anti-CEA Fab expressed in Escherichia coli.
    Chester KA; Robson L; Keep PA; Pedley RB; Boden JA; Boxer GM; Hawkins RE; Begent RH
    Int J Cancer; 1994 Apr; 57(1):67-72. PubMed ID: 8150543
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours.
    Francis RJ; Sharma SK; Springer C; Green AJ; Hope-Stone LD; Sena L; Martin J; Adamson KL; Robbins A; Gumbrell L; O'Malley D; Tsiompanou E; Shahbakhti H; Webley S; Hochhauser D; Hilson AJ; Blakey D; Begent RH
    Br J Cancer; 2002 Sep; 87(6):600-7. PubMed ID: 12237768
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma clearance of an antibody--enzyme conjugate in ADEPT by monoclonal anti-enzyme: its effect on prodrug activation in vivo.
    Rogers GT; Burke PJ; Sharma SK; Koodie R; Boden JA
    Br J Cancer; 1995 Dec; 72(6):1357-63. PubMed ID: 8519645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Coupling of a Novel TIMP3 Peptide to Carboxypeptidase G2 for Pro-Drug Activation at the Tumour Site.
    Aldughaim MS; Alsaffar F; Barker MD
    Molecules; 2021 Jan; 26(3):. PubMed ID: 33504102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical applications of phage-derived sFvs and sFv fusion proteins.
    Chester KA; Bhatia J; Boxer G; Cooke SP; Flynn AA; Huhalov A; Mayer A; Pedley RB; Robson L; Sharma SK; Spencer DI; Begent RH
    Dis Markers; 2000; 16(1-2):53-62. PubMed ID: 11360829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biodistribution of an antibody-enzyme conjugate for antibody-directed enzyme prodrug therapy in nude mice bearing a human colon adenocarcinoma xenograft.
    Stribbling SM; Martin J; Pedley RB; Boden JA; Sharma SK; Springer CJ
    Cancer Chemother Pharmacol; 1997; 40(4):277-84. PubMed ID: 9225945
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bacterial single-chain antibody fragments, specific for carcinoembryonic antigen.
    Ayala M; Dueñas M; Santos A; Vázquez J; Menéndez A; Silva A; Gavilondo JV
    Biotechniques; 1992 Nov; 13(5):790-9. PubMed ID: 1418981
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers.
    Wu AM; Chen W; Raubitschek A; Williams LE; Neumaier M; Fischer R; Hu SZ; Odom-Maryon T; Wong JY; Shively JE
    Immunotechnology; 1996 Feb; 2(1):21-36. PubMed ID: 9373325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2.
    Schepelmann S; Ogilvie LM; Hedley D; Friedlos F; Martin J; Scanlon I; Chen P; Marais R; Springer CJ
    Cancer Res; 2007 May; 67(10):4949-55. PubMed ID: 17510425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
    Pedley RB; Sharma SK; Boxer GM; Boden R; Stribbling SM; Davies L; Springer CJ; Begent RH
    Cancer Res; 1999 Aug; 59(16):3998-4003. PubMed ID: 10463598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preclinical characterization and in vivo imaging studies of an engineered recombinant technetium-99m-labeled metallothionein-containing anti-carcinoembryonic antigen single-chain antibody.
    Pietersz GA; Patrick MR; Chester KA
    J Nucl Med; 1998 Jan; 39(1):47-56. PubMed ID: 9443738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Disposition of the prodrug 4-(bis (2-chloroethyl) amino) benzoyl-L-glutamic acid and its active parent drug in mice.
    Antoniw P; Springer CJ; Bagshawe KD; Searle F; Melton RG; Rogers GT; Burke PJ; Sherwood RF
    Br J Cancer; 1990 Dec; 62(6):909-14. PubMed ID: 2257218
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant anti-carcinoembryonic antigen antibodies for targeting cancer.
    Chester KA; Mayer A; Bhatia J; Robson L; Spencer DI; Cooke SP; Flynn AA; Sharma SK; Boxer G; Pedley RB; Begent RH
    Cancer Chemother Pharmacol; 2000; 46 Suppl():S8-12. PubMed ID: 10950140
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.